BTK and thrombocytopenic purpura: In addition, BTK inhibitors were found to be beneficial in treating human systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, Sjogren's disease, graft versus host disease, and idiopathic thrombocytopenic purpura [26].